Affiliation:
1. Centro Hospitalar Vila Nova de Gaia/Espinho
2. ONCOMOVE® – Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Vila Nova de Gaia
3. University of Maia
4. Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia
5. ISEG, University of Lisbon
6. Centro Hospitalar Universitário do Porto
7. University of Aveiro
Abstract
Abstract
Purpose
To assess safety, satisfaction and overall adherence of a cardiac rehabilitation (CR) based framework for cancer patients at increased cardiovascular (CV) risk, compared to a community-based exercise training (CBET)
Methods
The CORE study (NCT05132998) was a single-center, prospective, randomized controlled trial enrolling cancer survivors exposed to cardiotoxic cancer treatment and/or with previous CV disease. Participants were randomized to an eight-week center-based CR program (CBCR) or CBET, twice a week. Overall feasibility (consent, retention, and completion rates) as well as intervention adherence (percentage of exercise session attended) and safety were assessed. Adverse events (AEs) were registered, and patients’ satisfaction was measured at the end of the study through a 5-item questionnaire.
Results
Eighty patients were included. The consent rate was 72.4%, and 77 (96.2%) patients started the study (retention rate 100% in CBCR vs 92.5% in CBET). The completion rate was 92.5%. Intervention adherence was higher in CBCR (90.3 ± 11.8% vs 68.4 ± 22.1%, p < 0.001). Exercise-related AEs were mainly musculoskeletal, accounting for exercise prescription modification in 47 sessions, none of them motivating exercise discontinuation. Major CV events were not reported. Patients revealed higher satisfaction in the CBCR (86.8% reported being very satisfied with the program vs 45.9% in CBET, p < 0.001).
Conclusion
The CORE trial suggests that both exercise-based interventions are feasible and safe in this setting. The higher intervention adherence and patient satisfaction in the CBCR group suggests that this comprehensive approach could be of interest in this patient population.
Publisher
Research Square Platform LLC